Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

17q aberrations in breast cancer

Author: Chris Jones

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

A number of known cancer genes map to the long arm of chromosome 17, among which ERBB2, BRCA1 and NME1 have been shown to be the most frequently involved in breast cancer. Recent reports have suggested the existence of at least four regions of allelic imbalance (AI) along 17q, one at 17q21, two in the 17q22-q24 region and one at 17q25. However, the nature of the anomalies involving these regions remains uncertain. …
Literature
1.
Orsetti B, Courjal F, Cuny M, Rodriguez C, Theillet C: 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene. 1999, 18: 6262-6270.CrossRefPubMed
Metadata
Title
17q aberrations in breast cancer
Author
Chris Jones
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66626

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue

Paper Report

Use of cDNA microarrays in breast cancer

Paper Report

Margin width influencing local recurrence in ductal carcinoma in situ

Paper Report

Edinburgh breast screening trial, 14 year follow up

Paper Report

ER in normal and pre-cancerous breast

Commentary

Endogenous hormones and the aetiology of breast cancer

Paper Report

Autologous stem-cell transplantation of hematopoietic cells containing the MDR1 cDNA
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits